ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease

Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European Society of Cardiology (ESC) Guidelines for the Management of Valvular Heart Disease. 

ESC 2021 | Novedades de las nuevas guías de valvulopatías de la Sociedad Europea de Cardiología

This new document was presented at the ESC 2021 Congress and simultaneously published in Eur Heart J.

These guidelines emphasize the importance of working as a team with surgeons to conduct personalized patient assessment.

This is the first time that clinical practice guidelines highly recommend involving patients in the decision-making process in gray areas, and having high-volume, specialized centers take on challenging cases.

Given the vast evidence on multiple procedures published, it no longer seems appropriate for referring cardiologists to refer patients directly to a surgeon or interventional cardiologist. The appropriate course of action would be referring the patient to a center specializing in valvular heart disease where the best team decision can be made (although this is far from what happens in daily clinical practice).

In aortic stenosis, age has come to play a leading role with class I recommendations.


Read also: ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate.


Surgery is recommended for patients <75 years old with low surgical risk or who are not candidates for transfemoral transcatheter aortic valve replacement (TAVR).

However, patients >75 years old or with high surgical risk (regardless of age) are candidates for TAVR.

For all other intermediate cases, both procedures are adequate, and the decision should be made according to the clinical, anatomical, and procedural characteristics discussed as a team and shared with the patient.


Read also: ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease.


Another important update is the recommendation to act early in aortic stenosis, aortic regurgitation, and mitral regurgitation.

Original Title: 2021 ESC/EACTS Guidelines for the management of valvular heart disease.

Reference: Alec Vahanian et al. Eur Heart J. 2021 Aug 28;ehab395. Online ahead of print. doi: 10.1093/eurheartj/ehab395. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

Hemodynamic Outcomes of Edge-to-Edge Repair in Degenerative and Functional Mitral Regurgitation

Transcatheter edge-to-edge mitral valve repair (M-TEER) has become an established therapeutic option for mitral valve disease. Among the available techniques, M-TEER using the MitraClip...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...